Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05930275
Registration number
NCT05930275
Ethics application status
Date submitted
27/06/2023
Date registered
5/07/2023
Titles & IDs
Public title
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Query!
Scientific title
A Multi-country, Prospective, Post-marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn's Disease for 3 Years in Real-world Clinical Practice (UPlift)
Query!
Secondary ID [1]
0
0
P23-899
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
UPlift
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Upadacitinib - Participants will receive upadacitinib as prescribed by their physician according to local label.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to Achieve First Clinical Response (CR) per Patient-Reported Outcome 2 (PRO2) (Daily CR-PRO)
Query!
Assessment method [1]
0
0
Daily CR-PRO is a composite endpoint defined as the first day with at least 30% decrease in daily very soft or liquid stool frequency (SF) and/or \>= 30% decrease in daily abdominal pain (AP) score and both not worse than baseline and a prospective 7-day average daily CR-PRO starting on the first day of daily CR-PRO; prospective 7-day average daily CR-PRO is defined as \>= 30% decrease in average daily very soft or liquid SF and/or \>= 30% decrease in average daily AP score and both not worse than baseline.
Query!
Timepoint [1]
0
0
Up to Week 12
Query!
Primary outcome [2]
0
0
Percentage of Participants Achieving Clinical Remission per Harvey Bradshaw Index (HBI) Among those with Clinical Response-Harvey Bradshaw Index (CR-HBI) at End of Induction Therapy
Query!
Assessment method [2]
0
0
Clinical Remission is defined as HBI \<= 4. Clinical Response is defined as HBI reduction \>= 3 points from baseline. The HBI is a simplified version of the Crohn's Disease Activity Index(CDAI). The HBI consists of 5 items encompassing patient reported (well-being, symptoms) and objective (presence of abdominal mass or complications) variables. The total HBI score is the sum of the values for each of the five items. Higher HBI scores indicate greater disease activity. Scores \< 5 indicate clinical remission, 5 - 7 indicate mild disease activity, 8 - 16 indicate moderate disease activity, and 16 indicate severe disease activity.
Query!
Timepoint [2]
0
0
At Week 52
Query!
Eligibility
Key inclusion criteria
* A diagnosis of moderate-to-severe crohn's disease (CD).
* Participants initiating upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study.
* Participants prescribed upadacitinib in accordance with the approved local label.
* Able to understand and communicate with the investigator and comply with the requirements of the study.
* Willing to continue with study documentation after cessation of upadacitinib.
* Willing and able to participate in the collection of PRO data via a cloud-based application on their personal or provided mobile phone or website app.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any contraindication to upadacitinib.
* Previously exposure to upadacitinib in a clinical trial.
* Currently participating in interventional research (not including non-interventional study, post-marketing observational study (PMOS) , or registry participation).
* Initiation of upadacitinib prior to enrollment.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/02/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/09/2028
Query!
Actual
Query!
Sample size
Target
1200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Blacktown Hospital /ID# 258574 - Blacktown
Query!
Recruitment hospital [2]
0
0
Mater Misericordiae Limited /ID# 258535 - South Brisbane
Query!
Recruitment hospital [3]
0
0
The Queen Elizabeth Hospital /ID# 258536 - Woodville South
Query!
Recruitment hospital [4]
0
0
Monash Medical Centre /ID# 258538 - Clayton
Query!
Recruitment hospital [5]
0
0
The Alfred Hospital /ID# 258537 - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [2]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [4]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [5]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
Canada
Query!
State/province [1]
0
0
Alberta
Query!
Country [2]
0
0
Canada
Query!
State/province [2]
0
0
British Columbia
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
Nova Scotia
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Ontario
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Quebec
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Guangdong
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Sichuan
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Alpes-Maritimes
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Auvergne-Rhone-Alpes
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Bouches-du-Rhone
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Gironde
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Haute-Corse
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Haute-Garonne
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Herault
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Ile-de-France
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Marne
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Nord
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Pays-de-la-Loire
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Pyrenees-Atlantiques
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Rhone
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Somme
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Cagnes Sur Mer
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Cholet
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Dijon
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Dreux
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Le Kremlin Bicetre
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Lyon
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Montpellier
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Paris
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Rennes
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Strasbourg cedex
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Nordrhein-Westfalen
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Saarland
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Schleswig-Holstein
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Berlin
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Hamburg
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Hannover
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Herne
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Magdeburg
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Tostedt
Query!
Country [41]
0
0
Greece
Query!
State/province [41]
0
0
Attiki
Query!
Country [42]
0
0
Greece
Query!
State/province [42]
0
0
Athens
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Hajdu-Bihar
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Vas
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Budapest
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Szeged
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Fukui
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Fukuoka
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Fukushima
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Hokkaido
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Ibaraki
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Iwate
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Kanagawa
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Saga
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Shiga
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Tochigi
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Chiba
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Mitaka
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Nishinomiya
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Osaka
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Sapporo
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Tokkyo
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Toyama
Query!
Country [64]
0
0
Netherlands
Query!
State/province [64]
0
0
Zuid-Holland
Query!
Country [65]
0
0
Romania
Query!
State/province [65]
0
0
Bucuresti
Query!
Country [66]
0
0
Romania
Query!
State/province [66]
0
0
Olt
Query!
Country [67]
0
0
Romania
Query!
State/province [67]
0
0
Bucharest
Query!
Country [68]
0
0
Romania
Query!
State/province [68]
0
0
Jassi
Query!
Country [69]
0
0
Romania
Query!
State/province [69]
0
0
Timi?oara
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Asturias
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Cordoba
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Las Palmas
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Vizcaya
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Granada
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Speed of onset and durability of effectiveness will be assessed. Upadacitinib is a drug approved for the treatment of CD. All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 1200 participants will be enrolled in approximately 230 sites across the world. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05930275
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ABBVIE INC.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Tanja Plath
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05930275